Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Abstract Background Neoadjuvant chemotherapy (NACT) is the prime approach to the management of locally advanced breast cancer (LABC). Influenced by different factors such as pathologic tumor characteristics, hormone receptor status, HER2 and proliferation marker expressions, response to therapy cann...

Full description

Bibliographic Details
Main Authors: Dena Firouzabadi, Amirreza Dehghanian, Alireza Rezvani, Laleh Mahmoudi, Abdolrasoul Talei
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Locally advanced breast cancer
Pathologic complete response
Neoadjuvant chemotherapy
ki67
Lymph node
Tumor-infiltrating lymphocytes
Online Access:https://doi.org/10.1186/s12885-020-07652-0

Internet

https://doi.org/10.1186/s12885-020-07652-0

Similar Items